Home › Compound Library › Sofosbuvir (Sovaldi)

Sofosbuvir (Sovaldi)

Antiviralprescriptionoral · inferred

HCV NS5B polymerase inhibitor, nucleotide prodrug rapidly converted intracellularly to active uridine triphosphate GS-461203 (via CES1, CatA, HINT1 and kinases). Plasma metabolite GS-331007 (inactive) is what is measured in PK. Rarely used alone; usually combined with an NS5A inhibitor (velpatasvir in Epclusa, ledipasvir in Harvoni). 12-week curative course.

Projected serum levels — 400 mg, once daily

Sofosbuvir (Sovaldi)
Sofosbuvir (Sovaldi) modeled serum levels, 400 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 50 100 150 200 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 400 mg once daily (oral).

Modeled steady state after ~1 days: peak ≈ 160 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a 400 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Antiviral
Route modeled
Oral
Model confidence
inferred
Half-life
42 min
Common dose
400 mg
Suggested maximum
400 mg/day
Reference dose range
200–400 mg (single dose)
Suggested cadence
once daily
Validated against
400 mg oral — Cmax 0.77 mg/L at 1 h

Documented interactions

  • moderate
    Apigenin + Sofosbuvir (Sovaldi) Transporter inhibition

    Apigenin inhibitor of BCRP may alter Sofosbuvir (Sovaldi) absorption / distribution

  • moderate
    Carvedilol (Coreg) + Sofosbuvir (Sovaldi) Transporter inhibition

    Carvedilol (Coreg) inhibitor of P-gp may alter Sofosbuvir (Sovaldi) absorption / distribution

  • moderate
    CBD (Cannabidiol) + Sofosbuvir (Sovaldi) Transporter inhibition

    CBD (Cannabidiol) inhibitor of P-gp may alter Sofosbuvir (Sovaldi) absorption / distribution

  • moderate
    Efavirenz (Sustiva) + Sofosbuvir (Sovaldi) Transporter induction

    Efavirenz (Sustiva) inducer of P-gp may alter Sofosbuvir (Sovaldi) absorption / distribution

  • moderate
    Fisetin + Sofosbuvir (Sovaldi) Transporter inhibition

    Fisetin inhibitor of BCRP may alter Sofosbuvir (Sovaldi) absorption / distribution

  • moderate
    Ginkgo Biloba (EGb 761) + Sofosbuvir (Sovaldi) Transporter inhibition

    Ginkgo Biloba (EGb 761) inhibitor of P-gp may alter Sofosbuvir (Sovaldi) absorption / distribution

Serum checks 26 modeled interaction pairings for sofosbuvir (sovaldi) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Clinical pharmacokinetics and pharmacodynamics of sofosbuvir and GS-331007 Kirby BJ et al. · Clinical Pharmacokinetics, 2015 DOI

    Comprehensive PK review of sofosbuvir and its active metabolite GS-331007, establishing 400 mg QD as the clinical dose.

  2. Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection Afdhal N et al. · New England Journal of Medicine, 2014 DOI

    ION-1 trial established 12-week sofosbuvir-based regimens for 94-99% SVR in HCV genotype 1.

2 published studies referenced in the app, each with a plain-language summary.